Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
ConditionGastrointestinal Tumors
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFujian Cancer Hospital
About this trial
The incidence of oxaliplatin allergy reactions is between 12-15%, while the incidence of severe (grade 3-4) allergic reactions is between 0.5-2%. The purpose of this study is to prospectively investigate the incidence of oxaliplatin allergy and neurotoxicity, and to evaluate the use of effective anti-allergic and desensitization therapies to enable patients who are already allergic to oxaliplatin to complete their prescribed doses smoothly.
Eligibility criteria
Qualifiers
Patients who plan to receive oxaliplatin treatment;
Male or female aged 18-75 year;
ECOG PS 0-2;
The expected survival time is more than 3 months;
Disqualifiers
None
Trial design
Treatments tested in this trial
- Anti-allergic treatment
Treatment groups
500 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov